Statistics on Biotechnology Use Results by fields of operation Total Sectors. Biotechnology indicators by execution sector. Unidades: Total 2021 Companies P.A. Higher Education PNPI Companies that perform R+D in Biotechnology 1.547 1.348 120 66 13 %Companies according to biotechnology used: Genetic code 38 31 87,5 89,4 46,2 %Companies according to biotechnology used: Functional Companies 44,8 38,4 88,3 93,9 53,8 %Companies according to biotechnology used: Cellular and tissue culturing and engineering 28,8 21,7 73,3 86,4 61,5 %Companies according to biotechnology used: Bioprocesses 53 50,3 58,3 93,9 69,2 %Companies according to biotechnology used: Sub-cellular organisms 14,8 8,2 53,3 74,2 38,5 %Companies according to biotechnology used: Bio-computing 30,7 24,1 73,3 87,9 30,8 %Companies according to biotechnology used: Nanobiotechnology 17,7 11,8 54,2 72,7 15,4 %Companies according to biotechnology used: Other 14,9 16,4 3,3 7,6 0 Companies in which biotechnology activities are: Main and/or exclusive 705 661 31 3 10 Companies in which biotechnology activities are: A secondary line of business 276 188 41 46 1 Companies in which biotechnology activities are: A tool necessary for production 567 500 48 17 2 %Companies by field(s) of ultimate application of biotechnology use: Human Health 50,5 45,8 76,7 95,5 69,2 %Companies by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture 17,8 15,3 17,5 69,7 23,1 %Companies by field(s) of ultimate application of biotechnology use: Food products 32,9 31,5 24,2 81,8 7,7 %Companies by field(s) of ultimate application of biotechnology use: Agriculture and forest production 25,7 23,7 22,5 72,7 23,1 %Companies by field(s) of ultimate application of biotechnology use: Environment 19 15,5 25,8 78,8 7,7 %Companies by field(s) of ultimate application of biotechnology use: Industry 15,8 13,4 14,2 68,2 7,7 Personnel in R&D in biotechnology (no. of persons) 47.144 15.744 15.418 15.757 225 Personnel in R&D in biotechnology (no. of persons): Research personnel 30.818 8.380 9.510 12.778 150 Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel 16.326 7.364 5.908 2.979 75 Personnel in R&D in biotechnology (no. of persons). Women 26.646 8.725 9.684 8.101 136 Personnel in R&D in biotechnology (no. of persons). Women. Research personnel 16.551 4.521 5.637 6.314 79 Personnel in R&D in biotechnology (no. of persons). Women. Technical and auxiliary personnel 10.095 4.204 4.047 1.787 57 Personnel in R&D in biotechnology (FTE) 32.896,3 11.523,2 11.271,7 9.934,5 166,9 Personnel in R&D in biotechnology (FTE): Research personnel 20.944,7 6.341,6 6.454,3 8.036 112,8 Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel 11.951,6 5.181,6 4.817,4 1.898,5 54,1 Personnel in R&D in biotechnology (FTE). Women 18.965,5 6.552,7 7.077,3 5.228 107,5 Personnel in R&D in biotechnology (FTE). Women: Research personnel 11.346 3.464,4 3.786,8 4.032,9 61,9 Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel 7.619,5 3.088,3 3.290,5 1.195,1 45,6 Internal expenditure on R&D (thousands of euros) 2.269.251 1.037.887 716.877 500.703 13.783 1) By nature of the expense: Current expenses 2.086.468 939.471 672.607 461.216 13.174 1.1) Remuneration to research personnel 872.151 321.525 252.863 293.131 4.630 1.2) Remuneration to technicians and auxiliary personnel 384.242 194.656 128.640 59.408 1.538 1.3) Other current expenses 830.076 423.290 291.103 108.677 7.006 2) By nature of the expense: Capital expenses 182.782 98.416 44.270 39.487 610 2.1) Land and buildings 20.257 10.150 2.712 7.373 23 2.2) Equipment and instruments 144.096 72.538 40.235 30.775 549 2.3) Acquisition of specific R+D software 8.151 5.713 1.102 1.303 33 2.4) Otros productos de propiedad intelectual específicos para I+D 10.278 10.015 222 36 5 1.1) By origin of the funds: Own funds 891.115 711.037 88.338 88.167 3.574 1.2) By origin of the funds: From companies 247.985 121.595 97.993 25.096 3.301 1.3) By origin of the funds: Public Administration funds 882.530 107.422 430.689 342.018 2.402 1.4) By origin of the funds: From Universities 3.851 192 1.388 2.220 50 1.5) By origin of the funds: From non profit private institutions 47.810 10.756 26.599 7.719 2.737 1.6) By origin of the funds: Foreign funds 195.959 86.884 71.871 35.483 1.720 Purchase of services R & D in Biotechnology to (thousands of euros) 174.817 145.440 23.461 3.058 2.858 Purchase of services R & D in Biotechnology to (thousands of euros): in Spain 123.416 95.870 21.807 3.035 2.704 Purchase of services R & D in Biotechnology to (thousands of euros): Abroad 51.401 49.570 1.654 23 154 %Companies that consider the following obstacles as very important considering biotechnology development: Access to capital 42,5 39,8 63,3 57,6 61,5 %Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information 11,9 12,5 6,7 9,1 15,4 %Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources 21,5 18,5 45 40,9 23,1 %Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain 13,3 11,2 26,7 33,3 7,7 %Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets 17,8 15,6 30 42,4 15,4 %Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and marketing channels 18,5 16,5 27,5 39,4 30,8 %Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception 15,6 16,1 10 12,1 30,8 %Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements 40,1 40 40 37,9 61,5 %Companies that consider the following obstacles as very important considering biotechnology development: Time / cost 54,4 53,9 58,3 57,6 61,5 %Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting 21,5 21,5 24,2 18,2 23,1 Notas: '..'=data not available '.'=numeric piece of data equal to zero not resulting from rounding FTE: Full Time Equivalent (*) Total calculated from the total number of companies with related activities with Biotechnology and the total Companies from other sectors with activities in R&D in Biotechnology Fuente: National Statistics Institute